Here is My Question:
Are those of us on Rituxan/Ocevrus considered immunocompromised?
People on anti-CD20 monoclonal antibodies (rituximab or Ocrelizumab) are selectively immunocompromised because of partial depletion of a subset of lymphocytes called B cells. B cells comprise approximately 20-25 % of circulating lymphocytes. The most common lymphocytes are CD3 positive T cells (70-75 %) and the least common at Natural Killer (NK) cells. Lymphocytes (T cells, B cells and NK cells), in turn, represent 20-40 % of total white blood cells in circulation.
True old-fashioned immunosuppression drugs (often called chemotherapy) tend to suppress or deplete many different types of white blood cells. For instance, cyclophosphamide (cytoxan) , a form of chemotherapy, kills off many types of lymphocytes as well as other types of white blood cells (neutrophils) in a dose dependent manner. This can cause a broad array of infectious and even neoplastic complications depending on the duration of use
Selective B cell depletion, at least with short term use, tends to be associated with far fewer infectious complications than more traditional immunosuppressants.
PLEASE NOTE: This information/opinions on this site should be used as an information source only. This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.